Related Experiment Video

Updated: May 10, 2026

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

TREM-1 inhibition attenuates inflammation and tumor within the colon

Jiangang Zhou1, Feng Chai, Guang Lu

  • 1Department of Oncology, Zhejiang Xiaoshan Hospital, Hangzhou, China.

International Immunopharmacology
|July 2, 2013
PubMed

Insights

Targeting TREM-1 (triggering receptor expressed on myeloid cells-1) can reduce colon inflammation and tumor growth. Inhibition of TREM-1 ameliorated colitis and associated tumorigenesis in a mouse model, suggesting a novel therapeutic strategy.

Area of Science:

  • Immunology
  • Gastroenterology
  • Oncology

Background:

  • Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies inflammation and is implicated in tumorigenesis.
  • The specific link between TREM-1, colon inflammation, and tumor development in vivo remains unclear.

Purpose of the Study:

  • To investigate if inhibiting the pro-inflammatory TREM-1 receptor can prevent aberrant inflammation and tumor development in the colon.
  • To explore TREM-1's role in linking colon inflammation and cancer.

Main Methods:

  • Utilized a mouse model of dextran sulfate sodium (DSS)-induced colitis and colitis-associated tumorigenesis.
  • Administered the TREM-1 antagonist LP17 or a control peptide during or after the induction of experimental colitis or tumorigenesis.
  • Assessed the effects of TREM-1 inhibition on inflammation, tumor development, and intestinal epithelial proliferation.

Main Results:

  • TREM-1 inhibition using LP17 treatment significantly ameliorated colon inflammation and tumor development.
  • LP17 demonstrated anti-inflammatory effects, reducing the severity of colitis.
  • TREM-1 inhibition also decreased intestinal epithelial proliferation in the DSS-induced colitis model.

Conclusions:

  • TREM-1 plays a critical role in both colon inflammation and tumor development.
  • Targeting TREM-1 presents a potential novel therapeutic strategy for managing colon inflammation and associated cancers.
  • Inhibition of TREM-1 offers a promising approach for treating inflammatory bowel disease and colorectal cancer.
Keywords:
ColonInflammationTREM-1Tumor development

More Related Videos

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.